Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vusolimogene oderparepvec
- Development stage
- Approved
- Lead developer
- Replimune
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral
01
Overview
Vusolimogene oderparepvec is a genetically engineered, replication-competent herpes simplex virus type 1 oncolytic immunotherapy developed by Replimune. The virus preferentially replicates in tumors, causing tumor-cell lysis and immunogenic release of tumor antigens. It is engineered to express granulocyte-macrophage colony-stimulating factor and the fusogenic glycoprotein GALV-GP-R-, intended to enhance local tumor destruction, recruit and activate immune cells, and induce systemic antitumor immunity. In the United States, it is marketed as TUDRIQEV and received accelerated approval in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed on an anti-PD-1 antibody-based regimen.
- Brand names
- TUDRIQEV
- Other names
- vusolimogene oderparepvec-wtpg
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on vusolimogene oderparepvec.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vusolimogene oderparepvec.